National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is a rare condition that can shorten life. Although the cause of this disease is usually unknown, in about 70% of heritable and 15-20% of idiopathic cases there is a change in a gene (a mutation) that controls how blood vessels grow and function. The gene is called bone morphogenetic protein type receptor 2 (BMPR2). Although mutations in BMPR2 are a risk factor for PAH, not everyone with a mutation gets the disease. Additional genetic and environmental factors are likely to contribute. The investigators suspect that mutations in other genes are responsible for some cases of PAH. In this study the investigators aim to recruit all patients with PAH and some of their relatives and follow them up for several years. The investigators hope to discover new mutations for this disease and to determine what factors lead to poor outcome, and to understand what triggers disease in patients with mutations.

Who can participate? Adults with PAH, their relatives and controls (one off blood sample)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722

Idiopathic Pulmonary Arterial Hypertension Heritable Pulmonary Arterial Hypertension Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo +1 more

RECRUITING

Registration Study for Rare Type of Pulmonary Hypertension

NCT03169010

Pulmonary Hypertension

RECRUITING

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

NCT02691689

Heart Defects, Congenital Pulmonary Arterial Hypertension Genetic Testing

RECRUITING NA

Identification of Heritable CTEPH

NCT03579862

Chronic Thromboembolic Pulmonary Hypertension

UNKNOWN

Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause

NCT00893178

Congestive Heart Failure Pulmonary Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

What does the study involve?

PAH patients will be seen at their local centre by their service team but they will have additional bloods taken. Relatives of PAH patients will be seen every year at their nearest PAH centre. Tests will include:

* Epidemiology Questionnaire to assess factors affecting health
* An echocardiogram (ECHO) to assess the size, shape, pumping action and the extent of any damage to the heart.
* Lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases.
* Optional right heart catheterisation (RHC) to determine how much blood your heart is pumping while you are resting and on exercise. Optional Cardiac Magnetic Resonance tests. To measure heart function. ( to be done only once)
* 6 minute walk test. To measure exercise capacity
* Cardiopulmonary exercise test. A bicycle exercise test, which will indicate how much blood your heart pumps while resting and with different levels of exercise.
* Electrocardiogram (ECG), a test that measures the electrical activity of the heart
* Blood tests

Controls:Blood sample and medical data collected once

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH

No interventions assigned to this group

Relatives and controls

Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, any age
* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, any age
* Has a family member diagnosed with idiopathic, anorexigen-induced, PVOD/PCH or heritable PAH

* Participant is willing and able to give informed consent for participation in the study.
* Self-reported to be healthy
* Age range up to 75 years

Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

* Patient is unable to give informed consent.
* Not suffering from idiopathic, anorexigen-induced, PVOD/PCH or heritable PAH

The participant may not enter the study if ANY of the following apply:

• Patient is unable to give informed consent.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes